Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | Director · PRESIDENT AND CEO | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,561,029 |
Ending reported balance
After 2026-08-18 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-08-18 · Exercise / conversion · Acquired 11,781 · Balance 5,488,984 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-08-18 · Tax withholding · Disposed 2,869 · Balance 5,486,115 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 3 · 2026-08-18 · Exercise / conversion · Acquired 22,100 · Balance 5,508,215 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 4 · 2026-08-18 · Tax withholding · Disposed 5,382 · Balance 5,502,833 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 5 · 2026-08-18 · Exercise / conversion · Acquired 29,002 · Balance 5,531,835 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 6 · 2026-08-18 · Tax withholding · Disposed 7,062 · Balance 5,524,773 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 7 · 2026-08-18 · Exercise / conversion · Acquired 57,212 · Balance 5,581,985 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 8 · 2026-08-18 · Tax withholding · Disposed 20,956 · Balance 5,561,029 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 27,494 |
Reported balance
After 2026-08-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-18 · Exercise / conversion · Disposed 11,781 · Balance 27,494 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 139,973 |
Reported balance
After 2026-08-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-18 · Exercise / conversion · Disposed 22,100 · Balance 139,973 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 299,694 |
Reported balance
After 2026-08-18 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-18 · Exercise / conversion · Disposed 29,002 · Balance 299,694 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 820,054 |
Reported balance
After 2026-08-18 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-08-18 · Exercise / conversion · Disposed 57,212 · Balance 820,054 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter.
F4: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.
F5: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter.
F6: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2025 Filed Aug 20, 2025 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 29,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022521 · form4-08202025_090803.xml · derivative · entry 12 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,701 Underlying: Common Stock · 29,002 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. F6 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 22,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022521 · form4-08202025_090803.xml · derivative · entry 11 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,373 Underlying: Common Stock · 22,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 11,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022521 · form4-08202025_090803.xml · derivative · entry 10 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,618 Underlying: Common Stock · 11,781 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 6,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022521 · form4-08202025_090803.xml · derivative · entry 9 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,272 Underlying: Common Stock · 6,758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 7,062 | $4.06 | $28,671.72 |
DisclosureSEC source: 0001415889-25-022521 · form4-08202025_090803.xml · nonDerivative · entry 8 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,314,417 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 29,002 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022521 · form4-08202025_090803.xml · nonDerivative · entry 7 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,321,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 5,382 | $4.06 | $21,850.92 |
DisclosureSEC source: 0001415889-25-022521 · form4-08202025_090803.xml · nonDerivative · entry 6 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,292,477 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 22,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022521 · form4-08202025_090803.xml · nonDerivative · entry 5 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,297,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,869 | $4.06 | $11,648.14 |
DisclosureSEC source: 0001415889-25-022521 · form4-08202025_090803.xml · nonDerivative · entry 4 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,275,759 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 11,781 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022521 · form4-08202025_090803.xml · nonDerivative · entry 3 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,278,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,646 | $4.06 | $6,682.76 |
DisclosureSEC source: 0001415889-25-022521 · form4-08202025_090803.xml · nonDerivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,266,847 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 6,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022521 · form4-08202025_090803.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,268,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 19,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013982 · form4-05212025_090536.xml · derivative · entry 12 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,703 Underlying: Common Stock · 19,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. F6 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 14,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013982 · form4-05212025_090536.xml · derivative · entry 11 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,473 Underlying: Common Stock · 14,733 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 7,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013982 · form4-05212025_090536.xml · derivative · entry 10 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,399 Underlying: Common Stock · 7,854 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 6,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013982 · form4-05212025_090536.xml · derivative · entry 9 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,030 Underlying: Common Stock · 6,758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 4,708 | $2.69 | $12,664.52 |
DisclosureSEC source: 0001415889-25-013982 · form4-05212025_090536.xml · nonDerivative · entry 8 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,261,735 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 19,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013982 · form4-05212025_090536.xml · nonDerivative · entry 7 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,266,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 3,588 | $2.69 | $9,651.72 |
DisclosureSEC source: 0001415889-25-013982 · form4-05212025_090536.xml · nonDerivative · entry 6 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,247,109 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 14,733 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013982 · form4-05212025_090536.xml · nonDerivative · entry 5 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,913 | $2.69 | $5,145.97 |
DisclosureSEC source: 0001415889-25-013982 · form4-05212025_090536.xml · nonDerivative · entry 4 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,235,964 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 7,854 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013982 · form4-05212025_090536.xml · nonDerivative · entry 3 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,237,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,646 | $2.69 | $4,427.74 |
DisclosureSEC source: 0001415889-25-013982 · form4-05212025_090536.xml · nonDerivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,230,023 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 6,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013982 · form4-05212025_090536.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,231,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:51 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 29,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007889 · form4-03122025_090352.xml · derivative · entry 6 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,206 Underlying: Common Stock · 29,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:51 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 15,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007889 · form4-03122025_090352.xml · derivative · entry 5 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,253 Underlying: Common Stock · 15,708 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:51 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 7,998 | $4.36 | $34,871.28 |
DisclosureSEC source: 0001415889-25-007889 · form4-03122025_090352.xml · nonDerivative · entry 4 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,224,911 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 10, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:51 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 29,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-007889 · form4-03122025_090352.xml · nonDerivative · entry 3 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,232,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:51 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 4,658 | $4.36 | $20,308.88 |
DisclosureSEC source: 0001415889-25-007889 · form4-03122025_090352.xml · nonDerivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,203,442 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 10, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:51 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 15,708 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-007889 · form4-03122025_090352.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,208,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 464,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007281 · form4-03062025_100358.xml · derivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 464,037 Underlying: Common Stock · 464,037 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (right to buy) · Derivative | 735,294 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001415889-25-007281 · form4-03062025_100358.xml · derivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735,294 Underlying: Common Stock · 735,294 shares Expires 2035-03-04 F1 · derivative.exercise_date: The shares subject to the option shall vest over 4 years with 1/48 of the total shares underlying the option vesting on April 4, 2025 and each month thereafter until fully vested. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 6,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004924 · form4-02202025_110246.xml · derivative · entry 3 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,788 Underlying: Common Stock · 6,758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,004 | $5.31 | $10,641.24 |
DisclosureSEC source: 0001415889-25-004924 · form4-02202025_110246.xml · nonDerivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,192,392 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 6,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-004924 · form4-02202025_110246.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,194,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 22,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027367 · form4-11202024_111121.xml · derivative · entry 9 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,673 Underlying: Common Stock · 22,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 11,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027367 · form4-11202024_111121.xml · derivative · entry 8 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,961 Underlying: Common Stock · 11,781 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 6,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027367 · form4-11202024_111121.xml · derivative · entry 7 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,546 Underlying: Common Stock · 6,758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 5,382 | $6.03 | $32,453.46 |
DisclosureSEC source: 0001415889-24-027367 · form4-11202024_111121.xml · nonDerivative · entry 6 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,187,638 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 22,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027367 · form4-11202024_111121.xml · nonDerivative · entry 5 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,193,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,869 | $6.03 | $17,300.07 |
DisclosureSEC source: 0001415889-24-027367 · form4-11202024_111121.xml · nonDerivative · entry 4 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,170,920 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 11,781 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027367 · form4-11202024_111121.xml · nonDerivative · entry 3 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,173,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,646 | $6.03 | $9,925.38 |
DisclosureSEC source: 0001415889-24-027367 · form4-11202024_111121.xml · nonDerivative · entry 2 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,162,008 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:21 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 6,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027367 · form4-11202024_111121.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,163,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 14, 2024 Filed Sep 16, 2024 22:26 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GiftCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023460 · form4-09162024_100916.xml · nonDerivative · entry 1 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,156,896 Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:24 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 22,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021858 · form4-08212024_100843.xml · derivative · entry 9 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,773 Underlying: Common Stock · 22,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:24 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 11,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021858 · form4-08212024_100843.xml · derivative · entry 8 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,742 Underlying: Common Stock · 11,781 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:24 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 6,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021858 · form4-08212024_100843.xml · derivative · entry 7 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,304 Underlying: Common Stock · 6,758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:24 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 5,382 | $5.53 | $29,762.46 |
DisclosureSEC source: 0001415889-24-021858 · form4-08212024_100843.xml · nonDerivative · entry 6 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,356,896 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:24 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 22,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021858 · form4-08212024_100843.xml · nonDerivative · entry 5 Jiang Wenbin · CIK 0001872873 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,362,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.